Evonik Industries AG EVK.DE
Composite 49/100; the shares have moved about 26% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Quality ranks 28/100 — a moderate mark against it.
Momentum ranks 77/100 — a strong point in its favour. Valuation ranks 62/100 — a slight point in its favour. Income ranks 57/100 — a slight point in its favour.
Quality ranks 28/100 — a moderate mark against it. Growth ranks 38/100 — a slight mark against it. Balance-sheet strength ranks 49/100 — a slight mark against it.
What the company does Evonik Industries AG is a specialty chemicals group with three segments: Advanced Technologies (polymers, methionine, silicas), Custom Solutions (additives for coatings and lubricants), and Infrastructure (plasticizers, butadiene, MTBE).
Key financials Profitability is weak: ROE 2%, ROA 3%, ROCE 4%; margins are thin (gross 24%, operating 7%, net 1%). Revenue fell 9% and EPS dropped 46% year-over-year. Debt/equity is 0.46 with net debt/EBITDA at 2.0x and interest coverage 2.6x.
Stock health Momentum is positive: 6-month return 44%, RSI 68, and dividend yield 6%. Sideravia scores Valuation 60/100 and Momentum 69/100, but Quality is only 27/100.
Price vs fair value The stock trades at a PREMIUM of 16.90% to our fair-value estimate of 14.57 and at a discount of 2.23% to the 12-month target of 17.93. - Forward P/E 20x vs trailing 50x (Valuation) - PEG 0.13 signals deep undervaluation relative to growth (Analyst) - FCF yield 14% supports cash returns (Valuation) - ROE 2% and margins 7% indicate weak profitability (Key Financials) - Piotroski F-Score 4/9 and Altman Z 2.0 reflect balance-sheet risk (Key Financials)
Looking forward Analysts expect forward P/E compression to 20x on modest growth, but execution on cost cuts and specialty margins will be key to justify the current premium.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-03, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.